These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33883258)

  • 21. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
    Caligiuri MA; Murray C; Robertson MJ; Wang E; Cochran K; Cameron C; Schow P; Ross ME; Klumpp TR; Soiffer RJ
    J Clin Invest; 1993 Jan; 91(1):123-32. PubMed ID: 7678599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
    Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
    Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.
    Geller MA; Cooley S; Judson PL; Ghebre R; Carson LF; Argenta PA; Jonson AL; Panoskaltsis-Mortari A; Curtsinger J; McKenna D; Dusenbery K; Bliss R; Downs LS; Miller JS
    Cytotherapy; 2011 Jan; 13(1):98-107. PubMed ID: 20849361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals.
    Robertson MJ; Cameron C; Lazo S; Cochran KJ; Voss SD; Ritz J
    Nat Immun; 1996-1997; 15(5):213-26. PubMed ID: 9390270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The two-pore domain K2 P channel TASK2 drives human NK-cell proliferation and cytolytic function.
    Schulte-Mecklenbeck A; Bittner S; Ehling P; Döring F; Wischmeyer E; Breuer J; Herrmann AM; Wiendl H; Meuth SG; Gross CC
    Eur J Immunol; 2015 Sep; 45(9):2602-14. PubMed ID: 26140335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
    Juliá EP; Amante A; Pampena MB; Mordoh J; Levy EM
    Front Immunol; 2018; 9():2140. PubMed ID: 30294328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Culturing the Human Natural Killer Cell Line NK-92 in Interleukin-2 and Interleukin-15 - Implications for Clinical Trials.
    Törnroos H; Hägerstrand H; Lindqvist C
    Anticancer Res; 2019 Jan; 39(1):107-112. PubMed ID: 30591446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.
    Roda JM; Joshi T; Butchar JP; McAlees JW; Lehman A; Tridandapani S; Carson WE
    Clin Cancer Res; 2007 Nov; 13(21):6419-28. PubMed ID: 17962339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
    Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
    Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients.
    Konjević G; Mirjačić Martinović K; Vuletić A; Babović N
    Melanoma Res; 2010 Dec; 20(6):459-67. PubMed ID: 20938360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A very long-acting IL-15: implications for the immunotherapy of cancer.
    Hangasky JA; Chen W; Dubois SP; Daenthanasanmak A; Müller JR; Reid R; Waldmann TA; Santi DV
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expansion of Human NK Cells Using K562 Cells Expressing OX40 Ligand and Short Exposure to IL-21.
    Kweon S; Phan MT; Chun S; Yu H; Kim J; Kim S; Lee J; Ali AK; Lee SH; Kim SK; Doh J; Cho D
    Front Immunol; 2019; 10():879. PubMed ID: 31105701
    [No Abstract]   [Full Text] [Related]  

  • 34. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
    Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
    Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients.
    Sosman JA; Fisher SG; Kefer C; Fisher RI; Ellis TM
    Ann Oncol; 1994 May; 5(5):447-52. PubMed ID: 7521206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potentiation of cytokine-induced proliferation of human Natural Killer cells by intravenous immunoglobulin G.
    Issekutz AC; Derfalvi B; Käsermann F; Rowter D
    Clin Immunol; 2015 Dec; 161(2):373-83. PubMed ID: 26307433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer.
    Shah MH; Freud AG; Benson DM; Ferkitich AK; Dezube BJ; Bernstein ZP; Caligiuri MA
    Clin Cancer Res; 2006 Jul; 12(13):3993-6. PubMed ID: 16818697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunological consequences of interleukin 12 administration after autologous stem cell transplantation.
    Pelloso D; Cyran K; Timmons L; Williams BT; Robertson MJ
    Clin Cancer Res; 2004 Mar; 10(6):1935-42. PubMed ID: 15041709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.
    Besson L; Charrier E; Karlin L; Allatif O; Marçais A; Rouzaire P; Belmont L; Attal M; Lombard C; Salles G; Walzer T; Viel S
    Front Immunol; 2018; 9():704. PubMed ID: 29706958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
    Gottschalk N; Lang S; Kimmig R; Singh M; Brandau S
    BMC Cancer; 2012 Oct; 12():451. PubMed ID: 23036052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.